Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.
about
Role of systemic chemotherapy in urothelial urinary bladder cancerMultimodal management of muscle-invasive bladder cancerPhase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer.Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.First- and second-line therapy for metastatic urothelial carcinoma of the bladderCKD-EPI and cockcroft-gault equations identify similar candidates for neoadjuvant chemotherapy in muscle-invasive bladder cancerChemotherapy in advanced bladder cancer: current status and futureSuccessful treatment of metastatic urothelial carcinoma arising in a transplanted renal allograft with paclitaxel, cisplatin, and gemcitabine combination therapy: a case report.Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10-17).Treatment of invasive bladder cancer: lessons from the past and perspective for the future.Novel strategies for treating relapsed/refractory urothelial carcinoma.Current chemotherapeutic strategies against bladder cancer.Chemotherapy for Muscle-Invasive Bladder Cancer.Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma.Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05)Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.Overexpression of ribonucleotide reductase subunit M1 protein predicts shorter survival in metastatic bladder cancer patients treated with gemcitabine-containing combination chemotherapy.Update on chemotherapy in the treatment of urothelial carcinoma
P2860
Q27010323-6956B031-AC98-4EE5-A714-111E63362425Q27011624-51556576-88CD-4514-918A-384ABCF927E6Q33341273-1D55C968-2715-4D2B-B2F1-DB81AA0A9F80Q33396202-7127E12A-138A-4DFC-8F3B-A9E69D88ED82Q33399928-89AA2E4C-7CB9-4D33-B84B-5635FFD27458Q34541463-7C17D9DD-A822-4F46-8244-249A32A5A31CQ35145440-7A556644-E1F5-44FF-A100-8BEEDE0E365AQ35227771-7BE26A1E-1CD9-4261-942E-21B37CBB3272Q35554515-4914E7B9-EABD-4931-AA78-7CF4A2A2FE32Q35677288-60E42A5A-55BA-4A12-A273-4A91C3B2EFE3Q35873130-1BEBE38B-EAA4-4CBE-BFB8-F2A08710D1E3Q36995686-400706A7-8A15-4A05-8C94-4B9194ADBF5AQ37888549-A5B88761-1194-4A28-AB7F-D0F51DFDC990Q38711504-16E43850-0BA3-4150-8E11-F2B06802766DQ42575965-F427B702-FDE4-43A0-84DF-ADCB820A636BQ43718098-74C49BC8-174B-43F3-A6CD-1B5B508A4E11Q44124156-ABE190E9-B817-4448-B327-308854F144BBQ51206876-CC0E6A6F-B6F4-4316-9ED9-7A6B9E153646Q58694390-39338D2B-ABED-4475-BF73-0080692FD5F5
P2860
Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Phase I-II study of paclitaxel ...... Oncology Genitourinary Group.
@ast
Phase I-II study of paclitaxel ...... Oncology Genitourinary Group.
@en
Phase I-II study of paclitaxel ...... Oncology Genitourinary Group.
@nl
type
label
Phase I-II study of paclitaxel ...... Oncology Genitourinary Group.
@ast
Phase I-II study of paclitaxel ...... Oncology Genitourinary Group.
@en
Phase I-II study of paclitaxel ...... Oncology Genitourinary Group.
@nl
prefLabel
Phase I-II study of paclitaxel ...... Oncology Genitourinary Group.
@ast
Phase I-II study of paclitaxel ...... Oncology Genitourinary Group.
@en
Phase I-II study of paclitaxel ...... Oncology Genitourinary Group.
@nl
P2093
P50
P1476
Phase I-II study of paclitaxel ...... h Oncology Genitourinary Group
@en
P2093
E Batiste-Alentorn
H Cortés-Funes
J Albanell
J Bellmunt
J J de la Cruz
L Paz-Ares
P304
P356
10.1200/JCO.2000.18.18.3247
P407
P577
2000-09-01T00:00:00Z